Medical Licensing (MD/DO) · Independent exam preparation
ABIM Interventional Cardiology Certification: Clinical Decision Guide Study Guide
Practise coronary revascularization, procedural planning, complication rescue, structural selection, and evidence interpretation for ABIM interventional cardiology.
By CertMedbry · Updated 18 October 2026
Choose appropriate revascularization, plan safer interventions, recognize procedural emergencies, and interpret physiology, imaging, and trial results. This guide develops 60 selected decisions across all nine domains of ABIM’s January 2026 certification blueprint. The official outline defines the full examination scope, including topics beyond this selective guide.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification pathway does this guide cover?
It covers ABIM’s initial Interventional Cardiology Certification Examination. ABIM lists certification and Maintenance of Certification separately; this guide uses the certification blueprint. The workbook label “ABIM - Subspecialty in Interventional Cardiology” refers to this examination, not a separate credential or general medical licensure examination.
ABIM Interventional Cardiology Certification Policies · ABIM Blueprints
How many questions are administered, and which questions count?
The January 2026 blueprint describes up to 220 single-best-answer multiple-choice questions. Approximately 35 are new questions that do not count toward the score. Because both figures are qualified, they should not be converted into a guaranteed exact scored-question count.
Interventional Cardiology Blueprint: Certification Examination (CERT), January 2026
What question styles and clinical tasks should candidates expect?
Most questions present patient scenarios involving diagnosis, test selection and interpretation, treatment, prognosis, epidemiology, or applied pathophysiology. Some require interpretation of angiograms, ventriculograms, IVUS, perfusion studies, CT, MRI, ECGs, echocardiograms, or peripheral vascular images. The 20 questions here are independent four-option learning drills, including clearly labeled original imaging schematics, and do not predict examination performance.
Interventional Cardiology Blueprint: Certification Examination (CERT), January 2026
What duration, delivery arrangements, and adaptivity are verified?
The January 2026 blueprint establishes the qualified question counts and single-best-answer format but does not specify duration, breaks, or adaptivity. Separately, ABIM’s current examination instructions describe approximately 10 hours, four sessions, a total break allowance of 100 minutes, and scheduling through Pearson VUE: https://www.abim.org/certification/becoming-certified-in-a-subspecialty/register-prepare-for-and-take-your-exam/interventional-cardiology/. Session capacity does not establish an exact administered question total, and these instructions do not establish adaptive administration.
Interventional Cardiology Blueprint: Certification Examination (CERT), January 2026 · ABIM Interventional Cardiology Certification Policies
Which blueprint version applies, and what changes are planned?
This guide follows the certification blueprint dated January 2026, linked by ABIM when verified on October 9, 2026. The document prints no separate effective date. ABIM’s expanded-blueprint schedule places Interventional Cardiology publication in January 2027 and certification implementation in fall 2027; that future outline is not the basis of this guide.
Interventional Cardiology Blueprint: Certification Examination (CERT), January 2026 · ABIM Expanded Blueprints
How are the official domains weighted?
The typical certification examination allocates Case Selection and Management 20%; Procedural Techniques 20%; Complications of Coronary Intervention 8%; Catheter-Based Management of Noncoronary Disease 13%; Basic Science 6%; Anatomy, Anatomic variants, Anatomic pathology 6%; Pharmacology 12%; Cardiac Imaging and Assessment 9%; and Miscellaneous 6%. Actual examination content may vary. The guide, questions, and cards approximate these weights while retaining every domain.
Interventional Cardiology Blueprint: Certification Examination (CERT), January 2026
This guide addresses the American Board of Internal Medicine Interventional Cardiology Certification Examination, a physician subspecialty board examination. Cardiovascular disease certification is an eligibility prerequisite, not the examination covered here. These independently authored learning materials are not official ABIM questions or an endorsed preparation resource.
Outline used: ABIM Interventional Cardiology Blueprint, Certification Examination (CERT), January 2026; current certification blueprint linked by ABIM on 2026-10-09. No separate effective date is printed. The workbook label 'ABIM - Subspecialty in Interventional Cardiology' maps to this official examination; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Case Selection and Management20%
1.When does refractory stable angina support revascularization?
Revascularization can improve symptoms when angina remains unacceptable despite guideline-directed medical therapy and a significant, treatable coronary stenosis explains the symptoms. The decision requires agreement between the clinical syndrome, ischemic territory, anatomy, and procedural feasibility. An angiographic narrowing alone does not establish that PCI will relieve symptoms. Distinguish symptom benefit from survival benefit, which depends on features such as left main disease, ventricular function, and the selected revascularization strategy.
Apply it
A patient remains limited by exertional chest pressure despite tolerated antianginal therapy. A focal coronary lesion supplies the ischemic territory. Discuss revascularization for symptom relief while separately explaining the evidence concerning prognosis.
Common pitfall: Do not promise a survival advantage from PCI solely because a stable patient has a severe-looking stenosis. Symptom relief and prognostic benefit require separate justification.
2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
2.Which patients with diabetes and multivessel disease favor CABG?
For patients with diabetes, multivessel coronary disease involving the LAD, and acceptable surgical candidacy, CABG is generally favored over PCI to reduce mortality and repeat revascularization. The comparison concerns the overall revascularization strategy rather than whether an individual lesion is technically stentable. Assess anatomic complexity, operative risk, life expectancy, and patient goals. A Heart Team is particularly useful when comorbidities or anatomy make the preferred strategy uncertain.
Apply it
A patient with diabetes has significant LAD, circumflex, and right coronary disease and acceptable operative risk. Refer for Heart Team consideration of CABG rather than selecting multivessel PCI simply because each stenosis appears accessible.
Common pitfall: Technical PCI feasibility does not erase the outcome evidence favoring CABG in suitable patients with diabetes and LAD-involving multivessel disease. Surgical risk still matters.
2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
3.How should significant left main disease change treatment selection?
Significant left main disease threatens a large myocardial territory and is a setting in which CABG improves survival compared with medical therapy alone. PCI is a reasonable alternative in selected patients when anatomy permits an equivalent revascularization result and clinical circumstances support it. Intermediate left main narrowing may require intravascular imaging or physiological assessment. Selection should integrate disease complexity, surgical risk, expected completeness of revascularization, and informed patient preference.
Apply it
An angiogram shows an intermediate distal left main narrowing with extensive downstream disease. Clarify lesion significance and obtain Heart Team input before committing to stenting based only on the initial visual estimate.
Common pitfall: A single angiographic projection can misclassify an intermediate left main lesion. Neither automatic PCI nor automatic dismissal is justified without assessing significance and treatment suitability.
2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
4.When does NSTE-ACS require an immediate invasive approach?
In NSTE-ACS, refractory ischemia or hemodynamic or electrical instability identifies patients who need an immediate invasive strategy rather than routine delayed evaluation. Persistent symptoms despite treatment suggest continuing jeopardized myocardium, while instability signals an immediate threat to circulation. Stable patients still require risk-based invasive planning, but a troponin result alone does not determine urgency. The decisive distinction is ongoing clinical danger rather than the absence of ST elevation.
Apply it
A patient with NSTEMI develops recurrent chest pain despite medical treatment and sustained ventricular tachycardia. Arrange immediate invasive evaluation while stabilizing the arrhythmia; a routine next-day angiogram would not address the current risk.
Common pitfall: Do not equate absence of ST elevation with permission to wait. Refractory ischemia, shock, or dangerous arrhythmia can make an NSTE-ACS presentation immediately urgent.
2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
5.Why should STEMI reperfusion decisions precede biomarker confirmation?
A compatible ischemic presentation with diagnostic ST elevation identifies a reperfusion emergency because persistent coronary occlusion causes progressive myocardial necrosis. Waiting for troponin confirmation can delay treatment without resolving the principal decision. Clinical assessment must still consider important mimics, especially aortic dissection when symptoms or examination suggest it. Reperfusion planning therefore combines rapid ECG interpretation, symptom assessment, contraindication screening, and activation of an appropriate STEMI system of care.
Apply it
A patient has ongoing crushing chest pain and diagnostic contiguous ST elevations shortly after symptom onset. Activate the reperfusion pathway immediately while evaluating clinical clues to dangerous mimics; do not wait for a second troponin.
Common pitfall: An initially normal troponin does not exclude an early coronary occlusion. Conversely, ST elevation must be interpreted with the clinical presentation rather than treated as context-free proof.
2025 Acute Coronary Syndromes Guideline: Top Things to Know · 2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
6.Which vessel should be treated first in infarction with cardiogenic shock?
Acute myocardial infarction complicated by cardiogenic shock requires emergency revascularization of the culprit vessel when appropriate. Routine immediate PCI of additional nonculprit vessels is not recommended because the added procedural burden can worsen outcomes. Restore flow to the infarct-related artery, support perfusion, and reassess the remaining disease after stabilization. This differs from the broader complete-revascularization strategy used in selected stable patients with ACS and multivessel disease.
Apply it
A patient with STEMI, hypotension, and pulmonary edema has an occluded right coronary artery plus severe stable LAD disease. Revascularize the culprit right coronary artery urgently and reassess the LAD after stabilization.
Common pitfall: Do not transfer the stable multivessel ACS recommendation directly into cardiogenic shock. More complete immediate angiographic treatment can impose harmful contrast, ischemic time, and procedural stress.
7.When does complete revascularization benefit stable multivessel ACS?
In appropriately selected patients with ACS and multivessel disease, complete revascularization is recommended, with the method and timing guided by anatomy and clinical circumstances. A stable patient after successful culprit PCI differs fundamentally from a patient in ongoing cardiogenic shock. Assess the significance of remaining lesions, renal function, procedural complexity, and suitability for PCI versus CABG. Complete treatment need not mean treating every visible narrowing during the first procedure.
Apply it
After uncomplicated culprit PCI for STEMI, a stable patient has a significant nonculprit lesion in another major vessel. Plan completion of revascularization using the remaining anatomy and clinical condition to choose timing and method.
Common pitfall: Do not equate complete revascularization with immediate treatment of every angiographic irregularity. Lesion significance, patient stability, and the safest overall revascularization strategy remain essential.
2025 Acute Coronary Syndromes Guideline: Top Things to Know · 2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
8.When is rescue PCI indicated after fibrinolysis?
Transfer to a PCI-capable center follows fibrinolysis regardless of apparent success. Assess reperfusion with symptoms, serial ECGs, and hemodynamic and electrical status. At approximately 60–90 minutes, insufficient ST resolution supports failure; the 2025 ACS guideline describes less than 50% resolution in anterior leads or less than 70% in inferior leads, measured using the lead with greatest baseline elevation or summed ST deviations. Calculate resolution as (baseline elevation minus follow-up elevation)/baseline elevation × 100%. Persistent ischemic pain, inadequate resolution, or instability requires immediate angiography and rescue PCI when appropriate. Do not wait for the scheduled ECG if the patient deteriorates. After apparently successful fibrinolysis in a stable patient, routine angiography with intent to perform PCI is recommended 2–24 hours after treatment. See the [2025 ACS guideline](https://www.ahajournals.org/hyp/doi/pdf/10.1161/CIR.0000000000001309).
Apply it
At 90 minutes after fibrinolysis for anterior STEMI, maximal ST elevation falls from 4 to 3 mm: resolution is 25%. Persistent pain reinforces failed reperfusion and the need for immediate rescue angiography. If pain resolves, ST elevation substantially normalizes, and stability persists, transfer still proceeds, with routine angiography in the 2–24-hour window.
Common pitfall: Fibrinolytic administration does not establish reperfusion. Do not delay rescue for ongoing ischemia or instability, and do not cancel transfer or routine early angiography after apparent success.
2025 Acute Coronary Syndromes Guideline: Top Things to Know · 2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
9.How does right ventricular infarction alter immediate assessment?
Right ventricular infarction can reduce left ventricular filling by impairing forward flow through the right heart. Inferior infarction accompanied by hypotension, elevated jugular venous pressure, and relatively clear lungs should prompt assessment for right ventricular involvement. Reperfusion remains central, while volume and vasoactive decisions require attention to right-sided filling and congestion. A preload-sensitive patient can deteriorate when venodilation or unnecessary volume depletion further reduces cardiac output.
Apply it
A patient with inferior STEMI becomes hypotensive and has distended neck veins without pulmonary crackles. Obtain right-sided ECG assessment and evaluate right ventricular function while arranging reperfusion and avoiding reflexive preload reduction.
Common pitfall: Clear lungs do not exclude severe infarct-related shock. Avoid automatically treating all post-infarction hypotension as left ventricular congestion requiring diuresis or venodilation.
2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
10.Which findings suggest acute severe mitral regurgitation after infarction?
Papillary muscle rupture after myocardial infarction can produce abrupt severe mitral regurgitation, pulmonary edema, and shock. The left atrium has not adapted to the sudden regurgitant volume, so pulmonary venous pressure rises rapidly. A murmur may be unimpressive when ventricular and atrial pressures equalize quickly. Urgent echocardiography identifies the mechanism and supports emergency surgical planning; a soft murmur must not delay assessment of a mechanically unstable patient.
Apply it
Several days after infarction, a patient develops sudden pulmonary edema and shock with a new but faint systolic murmur. Obtain urgent echocardiography to assess for papillary muscle rupture and mobilize surgical expertise.
Common pitfall: Do not use murmur loudness to exclude acute severe mitral regurgitation. Rapid pressure equalization and low output can make a catastrophic lesion sound deceptively mild.
2020 ACC/AHA Valvular Heart Disease Guideline Slide Set · 2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set · AHA Scientific Statement: Mechanical Complications of Acute Myocardial Infarction A Scientific Statement from the American Heart Association - PMC
11.How does a post-infarction ventricular septal rupture cause shock?
A ventricular septal rupture creates a new left-to-right shunt that diverts left ventricular output into the right ventricle and pulmonary circulation. Effective systemic output falls while pulmonary flow and right-sided loading increase. A new systolic murmur, rapid deterioration, and an oxygen-saturation step-up at the ventricular level support the diagnosis. Urgent echocardiography defines the defect and ventricular function, allowing rapid multidisciplinary planning for definitive repair and temporary stabilization.
Apply it
A patient deteriorates after infarction with a new harsh systolic murmur. Right heart sampling shows a substantial oxygen-saturation increase from right atrium to right ventricle. Obtain urgent echocardiography and involve the repair team.
Common pitfall: A new murmur with shock after infarction is not adequately explained by recurrent ischemia alone. Distinguish septal rupture from acute mitral regurgitation using imaging and shunt findings.
2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set · AHA Scientific Statement: Mechanical Complications of Acute Myocardial Infarction A Scientific Statement from the American Heart Association - PMC
12.What should secondary prevention address before ACS discharge?
Successful PCI treats the presenting obstruction but leaves the patient’s systemic atherosclerotic risk. Secondary prevention therefore includes an appropriate antithrombotic plan, intensive lipid lowering, smoking cessation, risk-factor management, and referral to cardiac rehabilitation. Medication access, bleeding risk, and the ability to follow the regimen affect whether the plan will work. Discharge preparation should connect each therapy to its purpose and provide a clear follow-up strategy for reassessment.
Apply it
A patient is ready for discharge after uncomplicated ACS PCI but reports difficulty paying for prescriptions. Reconcile the antiplatelet plan, address medication access, initiate appropriate lipid therapy, and arrange rehabilitation and follow-up.
Common pitfall: A technically successful stent does not complete ACS care. A prescription list without access planning, adherence discussion, and rehabilitation referral can leave major preventable risk untreated.
Procedural Techniques20%
13.Why is radial access preferred for many coronary interventions?
Radial access reduces access-site bleeding and vascular complications compared with femoral access and is recommended for suitable patients undergoing coronary intervention, particularly in ACS. Its superficial location allows effective compression without entering a large noncompressible space. Access selection still depends on arterial anatomy, equipment requirements, operator proficiency, and future vascular needs. The preferred route is the one that provides the required procedural capability while minimizing patient-specific access risk.
Apply it
A patient with ACS requires routine PCI and has suitable radial anatomy without a need for large-bore equipment. Select radial access as a practical way to reduce access-related bleeding while preserving procedural effectiveness.
Common pitfall: Radial preference is not a mandate to persist through unsuitable anatomy or equipment limitations. Repeated unsuccessful attempts can negate the expected advantage and delay necessary treatment.
2025 Acute Coronary Syndromes Guideline: Top Things to Know · 2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
14.How should ultrasound and fluoroscopy guide femoral puncture?
Safe femoral access targets the common femoral artery below the inguinal ligament and above its bifurcation, ideally where compression against the femoral head is feasible. Ultrasound identifies the bifurcation, vessel lumen, and anterior-wall calcium, while fluoroscopy supplies a bony landmark. Combining information reduces reliance on a skin crease or pulse alone. A high puncture increases retroperitoneal bleeding risk; a low puncture can involve branch vessels and complicate hemostasis. A high bifurcation or extensive calcium can narrow the usable access zone.
Apply it
Before femoral access, ultrasound shows a high bifurcation and anterior-wall calcification at the initially selected site. Choose a suitable common femoral segment using vessel imaging and the femoral head rather than the skin crease; reconsider the access route if no suitable segment exists.
Common pitfall: The inguinal skin crease does not reliably identify the inguinal ligament or arterial bifurcation. Palpable pulsation alone cannot confirm a safe common femoral puncture.
ACC Coronary Interventions Handbook, Chapter 3: Femoral Arterial Access
15.How should native-vessel versus SVG target selection and embolic protection be evaluated?
The 2021 revascularization guideline favors PCI of a feasible native coronary artery over a severely diseased SVG and considers embolic protection reasonable during SVG PCI when technically feasible. Subsequent randomized evidence qualifies a feasibility-only preference: PROCTOR randomized 220 patients, with one-year major adverse cardiac events in 34% after native-vessel PCI versus 19% after SVG PCI. The difference principally involved procedural infarction and repeat revascularization; a mortality advantage was not established. Compare native-target complexity, anticipated procedural risk, graft degeneration, protection-device feasibility, and expected durability rather than automatically choosing either target. PROCTOR abstract: https://pubmed.ncbi.nlm.nih.gov/41159978/.
Apply it
A severely diseased SVG supplies a territory whose native artery has a complex chronic total occlusion. Compare the risks of native recanalization with graft PCI rather than treating technical feasibility alone as decisive. If SVG PCI is selected, assess the distal landing zone and deliverability of embolic protection.
Common pitfall: Do not present the 2021 native-vessel preference as the entire evidence base, or convert PROCTOR into an automatic graft-PCI preference. A composite-event difference does not establish a mortality benefit.
2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
16.How does intravascular imaging improve assessment of coronary calcium?
Angiography may underestimate calcium that will prevent adequate stent expansion. Intravascular imaging characterizes calcium distribution and extent, including features such as circumferential involvement and longitudinal length; OCT can also assess thickness when visible. These findings help determine whether plaque modification is necessary before implantation. The procedural objective is sufficient lesion compliance for predictable expansion, rather than simply creating a channel wide enough to deliver an undeployed stent.
Apply it
A calcified lesion accepts a small balloon but remains resistant to expansion. Use intravascular imaging when feasible to define the calcium pattern and choose lesion preparation before committing to stent implantation.
Common pitfall: Successful wire or balloon passage does not prove that a lesion is ready for a stent. Unmodified circumferential calcium may permit delivery while preventing adequate expansion.
SCAI Publishes Expert Consensus Statement on Management of Calcified Coronary Lesions
17.Which lesion features guide calcium-modification equipment selection?
Calcium modification should match lesion crossability, balloon expansion, calcium morphology, and device compatibility. Atherectomy can facilitate treatment of selected severely calcified lesions, including situations where conventional balloons cannot cross or expand adequately. Intravascular lithotripsy requires delivery of its balloon and uses pressure waves to fracture calcium. No single device is universally preferred. Reassess lesion response after preparation so that the stent is implanted into an adequately modified segment.
Apply it
A heavily calcified stenosis is crossed by a wire but not by the intended balloon. Improve support and consider an appropriate plaque-modification strategy; do not assume that an undeliverable lithotripsy balloon can solve the immediate crossing problem.
Common pitfall: Choose a device that can reach and treat the lesion. A useful mechanism in theory is ineffective when vessel size, crossability, or equipment compatibility prevents safe deployment.
SCAI Publishes Expert Consensus Statement on Management of Calcified Coronary Lesions
18.When is provisional stenting appropriate for a coronary bifurcation?
A stepwise provisional strategy is appropriate for most coronary bifurcations because it treats the main vessel while avoiding unnecessary side-branch metal. The operator preserves side-branch access when needed, implants the main-vessel stent, optimizes its expansion, and reassesses side-branch flow and clinical significance. A second stent is reserved for a significant unresolved side-branch problem or selected complex anatomy requiring an intended two-stent strategy. Angiographic side-branch narrowing alone does not always justify escalation.
Apply it
After main-vessel stenting, a moderate side branch has an apparently narrowed ostium but preserved flow and no ischemic evidence. Complete appropriate optimization and assessment rather than automatically implanting a second stent.
Common pitfall: Do not treat every jailed side-branch ostium as a failed provisional strategy. Flow, ischemic relevance, dissection, and the amount of myocardium supplied guide additional treatment.
European Bifurcation Club 18th Expert Consensus Document, 2024
19.Why is proximal optimization important in bifurcation PCI?
A bifurcation main vessel is usually larger proximally than distally. A stent sized to the distal reference may therefore remain malapposed in its proximal segment. Proximal optimization uses an appropriately sized short balloon positioned within the proximal stent to improve expansion and apposition while respecting the carina. This also facilitates safer side-branch rewiring. Balloon size and position matter because inappropriate distal extension can distort the bifurcation and compromise the intended geometry.
Apply it
A stent sized to the distal main vessel has been placed across a bifurcation. Use a short balloon matched to the proximal vessel for proximal optimization before planned side-branch rewiring and further assessment.
Common pitfall: Do not size the entire stent to the larger proximal vessel or place the optimization balloon too distally. Both choices can injure or distort the distal bifurcation.
European Bifurcation Club 18th Expert Consensus Document, 2024
20.How should failure to deliver a coronary device be analyzed?
Device delivery failure can reflect inadequate guide support, severe tortuosity, calcification, an insufficiently prepared lesion, or a mismatch between equipment and anatomy. Identify where progression stops and distinguish failure to cross from failure to expand. Improve coaxial support and lesion preparation using a strategy appropriate to the mechanism. Forceful advancement can damage the vessel, deform equipment, or dissect the coronary ostium. During device exchanges, inspect the entire wire course and distal tip because migration into a small terminal branch can cause perforation.
Apply it
A balloon crosses a lesion, but a stent repeatedly stops at a proximal calcified bend. Reassess support and proximal lesion preparation instead of applying progressively greater force. Confirm that exchanges have not displaced the wire into a vulnerable distal branch.
Common pitfall: Repeated force is not a diagnostic maneuver. Determine the limiting mechanism before escalating equipment, and do not lose sight of the distal wire tip while concentrating on the target stenosis.
SCAI Publishes Expert Consensus Statement on Management of Calcified Coronary Lesions · ACC Coronary Interventions Handbook, Chapter 15: Management of Complications · SCAI: Management of Distal Coronary Artery Perforation
21.How should stent underexpansion influence repeat intervention?
An underexpanded stent leaves a restricted lumen and abnormal flow conditions that can contribute to restenosis and thrombosis. IVUS or OCT distinguishes inadequate scaffold expansion from neointimal tissue accumulation, neoatherosclerosis, and edge abnormalities that angiography alone may not resolve. Trace the strut contour separately from the lumen: a small scaffold area with little intervening tissue indicates underexpansion, whereas substantial tissue inside a sufficiently large scaffold indicates a biological narrowing. Treatment must address mechanical restriction with balloon optimization and additional calcium-directed methods when appropriate. Implanting another stent without correcting the original expansion problem can add metal while preserving the cause of failure.
Apply it
Compare the target and reference frames in the original IVUS schematic in the imaging question. Identify the smaller target strut contour, thin tissue layer, and bright external arc with shadowing. These findings support calcium-associated underexpansion and direct attention to expansion and calcium modification before considering additional metal.
Common pitfall: Do not assume every restenotic segment needs another stent or infer its mechanism solely from timing. Additional metal does not correct an unrecognized mechanical constraint.
SCAI Expert Consensus Statement on Management of In-Stent Restenosis and Stent Thrombosis · SCAI Expert Consensus Statement on Management of In-Stent Restenosis and Stent Thrombosis - PMC
22.When should chronic total occlusion PCI be considered?
Chronic total occlusion PCI is a specialized procedure whose proposed benefit should be tied to symptoms, ischemic territory, other coronary disease, and procedural risk. In patients with refractory angina despite medical treatment, symptom benefit remains uncertain under the 2021 revascularization guideline recommendation, even after other suitable lesions are treated. Discuss that uncertainty explicitly. Technical complexity, contrast exposure, radiation, and perforation risk make a clear patient-centered objective essential before attempting recanalization.
Apply it
A patient with persistent angina has a chronic total occlusion after other significant lesions have been addressed. Discuss potential symptom improvement, uncertainty of benefit, procedural complexity, and alternatives before referral to an experienced CTO program.
Common pitfall: An occluded artery is not itself proof that opening it improves survival or symptoms. Avoid substituting technical achievement for a justified clinical objective and informed discussion.
2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
23.How should long coronary lesions be prepared and stented?
Long lesions require assessment of reference dimensions, disease distribution, calcium, and suitable landing zones. A long diseased segment may vary substantially in diameter, so angiographic estimation alone can lead to undersizing, incomplete expansion, or an unhealthy stent edge. Intravascular imaging can guide preparation and optimization during complex PCI. The objective is adequate treatment of the significant disease with well-expanded stent segments and appropriate edges, while avoiding unnecessary additional metal.
Apply it
A long LAD lesion narrows within a tapering vessel and contains focal heavy calcium. Assess proximal and distal references, prepare the resistant segment, and plan stent dimensions and landing zones before deploying a long device.
Common pitfall: Do not choose a single diameter from the proximal vessel and assume it is safe throughout a tapering artery. Longitudinal disease assessment and segment-specific optimization matter.
2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set · SCAI Publishes Expert Consensus Statement on Management of Calcified Coronary Lesions
24.What does a damped coronary guide pressure waveform require?
Pressure damping during guide engagement can indicate that the catheter obstructs the ostium, is deeply seated, or has entered a small or diseased vessel opening. Continuing forceful injection may cause dissection or worsen ischemia. Stop injection, disengage sufficiently to restore an undamped aortic waveform, and reassess alignment and anatomy. A technically stable-looking catheter position is not acceptable when the pressure tracing signals impaired inflow or an unsafe relationship to the ostium.
Apply it
Immediately after engaging a coronary guide, the pressure waveform becomes markedly damped and the patient develops discomfort. Stop injection and disengage the catheter before selecting a safer position or alternative guide configuration.
Common pitfall: Do not respond to damping with a forceful test injection. The tracing may be the earliest warning of ostial obstruction, deep engagement, or impending catheter-induced dissection.
ACC Coronary Interventions Handbook, Chapter 15: Management of Complications · Prevention and Management of Left Main Coronary Artery Dissection | SCAI
Complications of Coronary Intervention8%
25.How is no-reflow distinguished from an epicardial obstruction?
No-reflow is inadequate myocardial perfusion despite an open epicardial artery, commonly involving distal embolization, microvascular vasoconstriction, edema, and reperfusion injury. Exclude guide-catheter ostial obstruction, dissection, thrombus, significant residual stenosis, and severe epicardial spasm before assigning the diagnosis. Epicardial flow and myocardial blush assess different levels of the circulation. Management addresses microvascular flow, including appropriately delivered intracoronary arteriolar vasodilators and correction of impaired perfusion pressure. Further stenting is unlikely to help when the main problem is downstream.
Apply it
After treating a thrombus-rich lesion, slow flow persists despite a disengaged guide, an undamped aortic waveform, a patent stent, and exclusion of dissection, significant residual narrowing, and major spasm. Assess perfusion pressure and treat the suspected microvascular problem rather than adding an empiric distal stent.
Common pitfall: A patent epicardial lumen does not guarantee tissue reperfusion. Conversely, persistent slow flow should not be labeled no-reflow while a correctable mechanical inflow problem remains unresolved.
SCAI: How to Prevent and Treat No Reflow Using Evidence-Based Measures · Prevention and Management of Left Main Coronary Artery Dissection | SCAI
26.How should distal coronary perforation be controlled initially?
Distal guidewire perforation allows blood to escape into the pericardial space and may cause delayed tamponade. Initial management includes recognizing the leak, limiting further extravasation with balloon occlusion when feasible, assessing hemodynamics, and obtaining urgent echocardiographic evaluation. Persistent distal leakage may require targeted embolization by an experienced operator. Maintain useful access and coordinate definitive control rather than simply withdrawing all equipment and assuming the small vessel will seal spontaneously.
Apply it
A distal wire tip is followed by persistent contrast extravasation. Position a balloon to limit inflow, obtain echocardiographic assessment, and prepare definitive distal-vessel treatment while monitoring closely for evolving hemodynamic compromise.
Common pitfall: A small distal perforation can still produce major tamponade. Apparent initial stability does not justify ignoring persistent leakage or abandoning monitoring after the procedure.
27.When does coronary perforation require emergency pericardial drainage?
Pericardial blood can rapidly raise intrapericardial pressure, impair chamber filling, and cause obstructive shock. Hypotension with a new effusion and echocardiographic evidence of tamponade during or after PCI requires urgent drainage while the coronary leak is controlled. Balloon occlusion treats continued inflow into the pericardium; pericardiocentesis relieves the existing external pressure on the heart. These actions address different mechanisms and may need to proceed together during resuscitation.
Apply it
During treatment of a coronary perforation, blood pressure falls and echocardiography shows an enlarging effusion with right-sided chamber collapse. Arrange immediate pericardial drainage while maintaining measures to control the arterial leak.
Common pitfall: Sealing the vessel does not immediately remove accumulated pericardial blood. Do not delay drainage of hemodynamically significant tamponade while waiting for balloon occlusion to restore pressure.
28.How should acute stent thrombosis be investigated after restoring flow?
Stent thrombosis can abruptly occlude a coronary artery and cause infarction, arrhythmia, or shock. Emergency PCI addresses the immediate obstruction, but prevention of recurrence requires identifying the cause. Intravascular imaging can reveal underexpansion, malapposition, edge problems, or other mechanical abnormalities. Review antiplatelet interruption, adherence, and clinical prothrombotic factors as well. Mechanical and pharmacological contributors may coexist, so a single apparently plausible explanation should not terminate the assessment.
Apply it
A patient presents with acute occlusion of a recently implanted stent after missing antiplatelet therapy. Restore flow urgently, then assess stent mechanics and medication access rather than attributing the event exclusively to missed tablets.
Common pitfall: Do not stop the evaluation after finding nonadherence. A correctable mechanical abnormality may coexist and continue to promote thrombosis even after antiplatelet treatment is restored.
SCAI Expert Consensus Statement on Management of In-Stent Restenosis and Stent Thrombosis
29.Which findings suggest retroperitoneal bleeding after femoral access?
Retroperitoneal hemorrhage may occur after femoral catheterization, particularly when access is too high to permit effective external compression. Blood can accumulate internally without a large visible groin hematoma. New hypotension, flank or back pain, and a falling hemoglobin concentration should trigger immediate concern. Stabilization and rapid bleeding assessment take priority, with imaging and definitive vascular management selected according to hemodynamic stability and the suspected source of ongoing hemorrhage.
Apply it
After femoral PCI, a patient develops back pain, hypotension, and a hemoglobin decline while the groin looks benign. Treat concealed hemorrhage as a serious possibility and initiate urgent stabilization and source assessment.
Common pitfall: A clean groin dressing does not exclude major access-related bleeding. The retroperitoneum can conceal substantial blood loss before superficial swelling or an obvious hematoma appears.
ACC Coronary Interventions Handbook, Chapter 15: Management of Complications
Catheter-Based Management of Noncoronary Disease13%
30.How does dobutamine distinguish true severe from pseudo-severe low-gradient aortic stenosis?
Gradient depends on flow as well as obstruction. Reduced-EF low-flow, low-gradient aortic stenosis can have a valve area at or below 1.0 cm², resting peak velocity below 4 m/s or mean gradient below 40 mm Hg, and LVEF below 50%. During low-dose dobutamine testing, measure stroke volume or flow, valve area, velocity, and mean gradient. Persistence of an area at or below 1.0 cm² as flow increases and velocity reaches at least 4 m/s or mean gradient reaches at least 40 mm Hg supports true severe obstruction. Substantial area enlargement above 1.0 cm² supports pseudo-severe disease. Inadequate flow augmentation can leave the study inconclusive.
Apply it
A patient has LVEF 30%, valve area 0.8 cm², and mean gradient 25 mm Hg. With increased flow during dobutamine, the area remains 0.8 cm² and the mean gradient rises to 43 mm Hg, supporting true severe stenosis. If flow barely increases, do not force a classification; review measurements and use complementary assessment such as CT valve-calcium scoring.
Common pitfall: A low resting gradient does not exclude severe stenosis. Failure to reach a high gradient during an inadequately augmented study also does not establish pseudo-severe disease.
31.How should symptomatic severe aortic stenosis guide TAVR versus SAVR selection?
Symptoms attributable to severe aortic stenosis support valve replacement. For patients suitable for a bioprosthesis, the 2020 guideline favors SAVR below age 65 or with life expectancy above 20 years; either SAVR or transfemoral TAVR at ages 65–80 when transfemoral anatomy permits; and transfemoral TAVR above age 80 or with life expectancy below 10 years when feasible. Integrate this guidance with individual circumstances and valve durability. Unsuitable transfemoral access, annular or coronary anatomy, aortopathy requiring repair, or another indication for cardiac surgery can favor SAVR. In high or prohibitive surgical risk, TAVR requires predicted survival beyond 12 months with acceptable quality of life. Predicted survival below 12 months or minimal expected quality-of-life improvement favors palliation.
Apply it
A healthy 60-year-old with long life expectancy generally favors SAVR. A 74-year-old with suitable transfemoral anatomy may reasonably choose either approach. An 84-year-old with feasible access and expected meaningful survival generally favors transfemoral TAVR; severe competing disease may instead favor palliation.
Common pitfall: Age guides selection but does not replace anatomical suitability, durability planning, surgical indications, or expected benefit.
32.Which rheumatic mitral stenosis features favor balloon commissurotomy?
Percutaneous mitral balloon commissurotomy is suited to selected patients with symptomatic severe rheumatic mitral stenosis, favorable valve morphology, less than moderate mitral regurgitation, and no left atrial thrombus. The procedure works by separating fused commissures, so heavily calcified or unfavorable subvalvular anatomy reduces suitability. Transesophageal echocardiography evaluates thrombus and regurgitation before intervention. Significant baseline regurgitation raises the risk that balloon treatment will produce an unacceptable additional valve leak.
Apply it
A symptomatic patient with severe rheumatic mitral stenosis has pliable leaflets and commissural fusion. Before balloon treatment, obtain TEE to exclude left atrial thrombus and establish that mitral regurgitation is less than moderate.
Common pitfall: Do not infer balloon suitability from a small valve area alone. Left atrial thrombus, moderate or greater regurgitation, and unfavorable anatomy materially change the procedural choice.
33.When is transcatheter edge-to-edge repair reasonable for secondary MR?
Secondary mitral regurgitation reflects ventricular or atrial remodeling rather than a primary leaflet lesion. Optimize heart-failure therapy, including resynchronization when indicated, before attributing persistent symptoms to a valve problem requiring intervention. The 2020 guideline supports TEER in selected patients with persistent symptomatic severe secondary MR, suitable anatomy, LVEF 20%–50%, LV end-systolic diameter no greater than 70 mm, and pulmonary artery systolic pressure no greater than 70 mm Hg. Selection matters because ventricular disease remains central.
Apply it
A patient remains symptomatic with severe secondary MR despite optimized heart-failure therapy. Review ventricular dimensions, ejection fraction, pulmonary pressure, and TEE anatomy before deciding whether the guideline-supported TEER selection criteria are met.
Common pitfall: Do not apply secondary-MR TEER criteria to primary degenerative disease. Also avoid treating an unoptimized ventricle as though the valve leak were an isolated primary disorder.
34.How is the ankle-brachial index interpreted?
The resting ankle-brachial index compares ankle systolic pressure with brachial systolic pressure and helps detect lower-extremity PAD. The 2024 guideline classifies ABI as abnormal at 0.90 or less, borderline at 0.91–0.99, normal at 1.00–1.40, and noncompressible above 1.40. Interpret the result with symptoms and examination. Exertional leg symptoms with a normal or borderline resting ABI may require exercise ABI testing rather than dismissal of an arterial cause.
Apply it
A patient has reproducible calf discomfort with walking and a resting ABI of 0.96. Recognize the borderline result and consider exercise ABI testing to evaluate whether exertion reveals a hemodynamically significant arterial limitation.
Common pitfall: Do not label every ABI above 0.90 reassuring. Borderline values and exercise-related symptoms can require further testing, while unusually high values may reflect noncompressible arteries.
35.Which test helps when ankle arteries are noncompressible?
An ABI above 1.40 suggests noncompressible ankle arteries, often related to medial arterial calcification. The measured ankle pressure can be falsely high despite obstructive PAD. Toe pressure and the toe-brachial index, assessed with waveforms, help evaluate perfusion because digital arteries are less often noncompressible. A TBI of 0.70 or less is abnormal. This distinction is particularly useful in diabetes or chronic kidney disease, where a high ABI can otherwise mask clinically important ischemia.
Apply it
A patient with diabetes has a nonhealing toe wound and an ABI of 1.55. Obtain toe pressure or TBI with waveforms rather than interpreting the high ankle pressure as evidence that limb perfusion is excellent.
Common pitfall: A high ABI is not a stronger version of a normal ABI. Noncompressibility can conceal obstructive disease and should redirect physiological testing toward the toes and waveforms.
36.When does chronic limb-threatening ischemia require revascularization assessment?
Chronic limb-threatening ischemia involves chronic ischemic rest pain, nonhealing wounds, or gangrene attributable to objectively demonstrated arterial disease. The clinical aim extends beyond walking distance to wound healing, pain relief, preservation of functional tissue, and prevention of major amputation. Revascularization assessment should integrate perfusion, arterial anatomy, wound severity, infection, comorbidities, and patient goals. Wound care and infection management remain necessary because restoring arterial flow alone does not resolve every barrier to healing.
Apply it
A patient has persistent forefoot rest pain and a nonhealing ulcer with objectively impaired perfusion. Arrange limb-preservation and revascularization assessment alongside wound and infection care rather than offering an exercise program as the sole response.
Common pitfall: Do not manage tissue loss as uncomplicated claudication. Conversely, a wound alone does not prove arterial causation; establish perfusion impairment and evaluate competing causes of poor healing.
37.When is revascularization reasonable for functionally limiting claudication?
For claudication, revascularization primarily seeks to improve walking function and quality of life. Guideline-directed medical therapy and structured exercise are foundational treatments. Revascularization is reasonable when symptoms remain functionally limiting despite an adequate treatment program and a hemodynamically significant lesion offers a suitable target. Discuss expected durability, procedural risk, and the possibility of repeat intervention. Anatomic stenosis without meaningful symptoms is not equivalent to an indication for elective limb intervention.
Apply it
A patient remains unable to perform essential daily walking despite medical therapy and structured exercise. Confirm a significant arterial lesion and discuss revascularization based on symptom burden, anatomy, durability, and procedural risk.
Common pitfall: Do not stent an incidental peripheral stenosis simply because it is visible. For claudication, the decision depends on functional limitation and response to foundational therapy.
43.How are systemic flow, pulmonary flow, and shunt ratio calculated by oxygen mass balance?
The Fick principle divides oxygen consumption by the relevant arteriovenous oxygen-content difference. Systemic flow Qs = oxygen consumption/(systemic arterial content − pre-shunt mixed venous content); pulmonary flow Qp = oxygen consumption/(pulmonary venous content − pulmonary arterial content). Thus Qp/Qs is the systemic content difference divided by the pulmonary content difference. Use consistent units, steady-state sampling, and an appropriate pre-shunt mixed venous estimate. With a left-to-right shunt, pulmonary arterial blood is oxygen-enriched and cannot simply replace pre-shunt mixed venous blood when calculating systemic flow.
Apply it
In a hypothetical steady-state study, oxygen consumption is 250 mL/min, systemic arterial and pulmonary venous contents are each 200 mL/L, pre-shunt mixed venous content is 150 mL/L, and pulmonary arterial content is 175 mL/L. Qs = 250/50 = 5 L/min; Qp = 250/25 = 10 L/min; Qp/Qs = 2.0, indicating pulmonary flow twice systemic flow. Closure decisions also require anatomy, chamber effects, and pulmonary vascular assessment.
Common pitfall: Do not confuse oxygen saturation with oxygen content, mix mL/dL with mL/L, or label pulmonary flow as systemic cardiac output when a substantial shunt is present. An oxygen step-up localizes a shunt; its magnitude alone does not determine operability.
Interventional Cardiology Blueprint: Certification Examination (CERT), January 2026 · AHA Scientific Statement: Mechanical Complications of Acute Myocardial Infarction A Scientific Statement from the American Heart Association - PMC
Basic Science6%
38.How does neointimal hyperplasia produce in-stent restenosis?
Stent implantation injures the vessel wall and initiates a healing response involving smooth-muscle cell proliferation and extracellular matrix accumulation. The resulting neointimal tissue can narrow the lumen within the stent. Drug-eluting stents suppress this proliferative response but do not eliminate every cause of restenosis. Mechanical underexpansion and later neoatherosclerosis are different mechanisms. On OCT, a relatively homogeneous tissue layer within the strut contour supports hyperplasia; compare scaffold area with lumen area rather than judging lumen size alone.
Apply it
In the original OCT schematic in the restenosis question, trace the outer strut contour and inner luminal boundary. A large scaffold enclosing a thick uniform tissue ring and small lumen supports tissue-driven narrowing. Establish this mechanism before choosing lesion preparation and antiproliferative treatment.
Common pitfall: Restenosis is a descriptive finding, not a single mechanism. A homogeneous OCT pattern supports hyperplasia but is not histological proof; review the complete pullback for mixed mechanisms.
ACC Coronary Interventions Handbook, Chapter 8: In-Stent Restenosis · SCAI Expert Consensus Statement on Management of In-Stent Restenosis and Stent Thrombosis - PMC
39.Why can neoatherosclerosis cause late stent failure?
Neoatherosclerosis is the development of atherosclerotic change within the neointima of a previously stented segment. Lipid accumulation and inflammatory changes can create a plaque-like substrate that narrows the lumen or becomes unstable. It therefore differs from uncomplicated early neointimal proliferation and can contribute to late restenosis or thrombosis. Intravascular imaging helps characterize the tissue and associated mechanical findings, allowing late stent failure to be evaluated as a mechanism-based problem.
Apply it
Years after PCI, a patient develops an acute coronary syndrome within a previously stable stent. Imaging shows lipid-rich neointimal change. Consider neoatherosclerosis as a potential substrate rather than assuming the original stent simply became too small.
Common pitfall: Do not treat an old stent as biologically inert. Late failure can reflect new atherosclerotic tissue changes, and the clinical presentation may be acute rather than gradually progressive.
ACC Coronary Interventions Handbook, Chapter 8: In-Stent Restenosis
40.How do platelet activation and coagulation cooperate in coronary thrombosis?
Vascular injury exposes thrombogenic surfaces. Platelet adhesion involves von Willebrand factor and platelet glycoprotein Ib; activation signals, including ADP through P2Y12, promote glycoprotein IIb/IIIa activation and fibrinogen-mediated platelet aggregation. Tissue factor initiates coagulation through factor VIIa, leading to factor Xa generation and thrombin formation. Thrombin converts fibrinogen to fibrin and also activates platelets, linking the systems. P2Y12 inhibition limits platelet activation, whereas heparin-mediated anticoagulation or direct thrombin inhibition limits coagulation. Neither mechanism provides an interchangeable substitute for the other.
Apply it
During PCI, explain why a patient may need both a P2Y12 inhibitor and a procedural anticoagulant: one suppresses platelet signaling and aggregation, while the other reduces thrombin-mediated clot formation. Their combined antithrombotic effects also increase bleeding risk.
Common pitfall: Do not equate platelet inhibition with anticoagulation or assume a normal platelet count excludes active platelet-driven thrombosis. Thrombus formation depends on platelet function and coagulation activity as well as cell number.
Interventional Cardiology Blueprint: Certification Examination (CERT), January 2026 · DailyMed - KENGREAL- cangrelor injection, powder, lyophilized, for solution · DailyMed: Prasugrel Prescribing Information · 2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
Anatomy, Anatomic variants, Anatomic pathology6%
41.What determines coronary dominance?
Coronary dominance is defined by the arterial origin of the posterior descending artery rather than by the relative diameter of the right and left coronary arteries. In right dominance, the posterior descending artery arises from the right coronary artery; in left dominance, it arises from the circumflex system. Recognizing the pattern helps identify the myocardium jeopardized by an occlusion and interpret inferior-wall perfusion. Codominant arrangements require description of the actual posterior circulation.
Apply it
Angiography shows the posterior descending artery arising from the circumflex despite a sizeable right coronary artery. Describe the circulation as left dominant and consider that distribution when estimating myocardium at risk from circumflex disease.
Common pitfall: Do not define dominance by which coronary artery looks largest or supplies the most visible branches. Trace the posterior descending artery to its origin.
STS Adult Cardiac Surgery Database Training Manual, Version 2.9, November 2018
42.Which anatomical and clinical findings determine surgery for an anomalous coronary artery?
Define the ostium and proximal course with coronary CT angiography when invasive views are insufficient. A right-origin circumflex commonly follows a retroaortic course, which differs from an opposite-sinus artery with intramural or interarterial anatomy. For anomalous aortic origin of a coronary artery (AAOCA), the 2025 congenital-heart guideline recommends surgery when symptoms or diagnostic ischemia are attributable to the anomaly. Surgery is reasonable for an asymptomatic anomalous left coronary origin with high-risk anatomy: ostial or proximal stenosis, a slit-like orifice, an acute takeoff angle, or an intramural course. In asymptomatic opposite-sinus AAOCA without ischemia or compromised perfusion, surgical benefit is uncertain; observation or surgery may be reasonable after individualized assessment. See the [2025 congenital-heart guideline](https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000001402).
Apply it
Exertional syncope with a left coronary artery arising from the right sinus requires anatomical and ischemic assessment. Attributable ischemia supports surgery. Even without symptoms, a slit-like ostium and intramural left coronary course support considering surgery; an asymptomatic patient without compromised perfusion has a less certain benefit.
Common pitfall: Opposite-sinus origin alone does not establish identical risk or an automatic surgical indication. Distinguish attributable ischemia, high-risk left coronary anatomy, and an asymptomatic anomaly without perfusion compromise.
Interventional Cardiology Blueprint: Certification Examination (CERT), January 2026 · 2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
44.Why is the posteromedial papillary muscle particularly vulnerable to infarction?
The posteromedial papillary muscle usually has a single arterial supply from the right coronary or circumflex system, depending on dominance. The anterolateral papillary muscle has dual supply from the LAD and circumflex systems. Loss of the single supplying territory therefore makes posteromedial rupture more likely, particularly after inferior or lateral infarction. Either papillary muscle supports chordae to both mitral leaflets, so the resulting regurgitant anatomy should be established by echocardiography rather than inferred from leaflet names alone.
Apply it
After an inferior infarction, a patient develops a mobile papillary muscle segment and acute severe MR. Trace the dominant posterior coronary supply and recognize the anatomical vulnerability of the posteromedial muscle while arranging definitive valve assessment.
Common pitfall: Do not assume the right coronary artery always supplies the posteromedial papillary muscle; coronary dominance changes the supplying vessel. Dual supply makes anterolateral rupture less common, not impossible.
Pharmacology12%
45.When is prasugrel contraindicated despite an indication for antiplatelet therapy?
Prasugrel irreversibly inhibits platelet P2Y12 receptors after metabolic activation, reducing ADP-mediated platelet activation. Its prescribing information contraindicates use in patients with prior stroke or transient ischemic attack because of increased harm, including bleeding. Active pathological bleeding is another contraindication. The presence of ACS and planned PCI does not override these restrictions. Antiplatelet selection must incorporate cerebrovascular history, current bleeding, age, body weight, and the broader ischemic-versus-bleeding balance.
Apply it
A patient undergoing PCI for ACS reports a remote transient ischemic attack without residual deficit. Exclude prasugrel from the treatment choices and select an alternative P2Y12 strategy appropriate to the remaining clinical circumstances.
Common pitfall: A remote or fully resolved TIA still counts. Do not treat absence of neurological disability as permission to use prasugrel in a patient with that history.
46.How does CYP2C19 poor-metabolizer status affect clopidogrel treatment?
Clopidogrel is a prodrug whose activation depends partly on CYP2C19. Poor metabolizers generate less active metabolite, resulting in reduced platelet inhibition and higher ischemic risk in settings such as ACS and PCI. CPIC recommends avoiding clopidogrel when possible in this setting and using an alternative such as ticagrelor or prasugrel if clinically appropriate. Genotype guides selection after a result is available; it does not remove the need to check alternative-drug contraindications.
Apply it
A patient with ACS PCI is known to carry two CYP2C19 no-function alleles. Prefer an appropriate alternative to clopidogrel, checking cerebrovascular history and other contraindications before choosing the replacement P2Y12 inhibitor.
Common pitfall: Do not respond to reduced clopidogrel activation by assuming every alternative is safe. A history of stroke or TIA still excludes prasugrel despite the genotype-based reason to switch.
CPIC Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update · DailyMed: Prasugrel Prescribing Information
47.How should cangrelor be transitioned to an oral P2Y12 inhibitor?
Cangrelor provides rapid, reversible intravenous P2Y12 inhibition without gastrointestinal absorption, but platelet function recovers within about an hour after discontinuation. During infusion, cangrelor prevents effective receptor binding by the active metabolites of clopidogrel and prasugrel. The prescribing information specifies ticagrelor 180 mg at any time during infusion or immediately afterward, prasugrel 60 mg immediately afterward, or clopidogrel 600 mg immediately afterward. Select the oral agent subject to patient-specific contraindications. Do not administer clopidogrel or prasugrel during the infusion.
Apply it
An intubated patient undergoes urgent PCI with cangrelor before oral P2Y12 treatment. If ticagrelor is appropriate and enteral administration is feasible, its loading dose may be given during the infusion. If choosing clopidogrel or prasugrel, administer the specified loading dose immediately after cangrelor is stopped.
Common pitfall: Giving clopidogrel or prasugrel during cangrelor infusion can leave ineffective oral platelet inhibition after cangrelor wears off. A transition plan must specify the drug, dose, and timing; platelet inhibition also does not replace procedural anticoagulation.
DailyMed - KENGREAL- cangrelor injection, powder, lyophilized, for solution · 2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
48.How does prior HIT change procedural anticoagulant selection?
Heparin-induced thrombocytopenia is a prothrombotic immune reaction, so a falling platelet count in this setting does not imply protection from thrombosis. For PCI in a patient with HIT, a suitable nonheparin anticoagulant such as bivalirudin or argatroban replaces unfractionated heparin. Bivalirudin directly inhibits thrombin rather than relying on antithrombin-mediated activity. Selection and monitoring must account for the patient’s clinical state, organ function, and the procedural anticoagulation plan.
Apply it
A patient with documented HIT requires coronary intervention. Plan a nonheparin procedural anticoagulant and check all sources of potential heparin exposure instead of merely reducing the usual unfractionated heparin dose.
Common pitfall: Do not interpret thrombocytopenia as evidence that anticoagulation is unnecessary. HIT can generate intense thrombosis, and lowering the heparin dose does not remove the immune trigger.
2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
49.How should contrast-associated kidney risk alter PCI planning?
Chronic kidney disease increases the risk of acute kidney injury around coronary angiography, but contrast exposure is only one possible contributor. Hemodynamic instability, volume status, and other nephrotoxic insults also matter. Risk reduction includes appropriate hydration, minimizing contrast volume, and avoiding unnecessary repeat injections. Balance renal protection against the urgency of the coronary indication: concern about kidney injury should shape an emergency procedure rather than automatically prevent indicated lifesaving reperfusion.
Apply it
A patient with chronic kidney disease needs urgent PCI for ongoing ischemia. Plan hydration appropriate to cardiac status, track and minimize contrast use, and avoid redundant angiographic runs while proceeding with necessary revascularization.
Common pitfall: Do not attribute every postprocedural creatinine rise solely to contrast. Also avoid reflexive large-volume hydration in a congested patient or withholding urgent reperfusion solely because renal risk exists.
2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
50.How should long-term anticoagulation modify antiplatelet therapy after ACS PCI?
Combining oral anticoagulation, aspirin, and a P2Y12 inhibitor increases bleeding risk. In patients requiring long-term anticoagulation after ACS PCI, the 2025 guideline recommends discontinuing aspirin after 1–4 weeks while continuing an oral anticoagulant and a P2Y12 inhibitor, preferably clopidogrel. The exact plan must balance early stent-related ischemic risk with bleeding risk. This strategy differs from the default antiplatelet approach in patients who have no independent indication for oral anticoagulation.
Apply it
A patient with atrial fibrillation requiring long-term anticoagulation undergoes ACS PCI. Develop a time-limited aspirin plan and specify the continuing anticoagulant-plus-P2Y12 regimen, including the date and rationale for reassessment.
Common pitfall: Do not continue triple therapy indefinitely by default. Conversely, stopping all antiplatelet therapy immediately after stenting ignores early coronary thrombosis risk and requires a different clinical justification.
51.How does very-high-risk ASCVD classification determine current lipid goals?
The 2026 guideline defines very-high-risk ASCVD as at least two major events or one major event plus at least two high-risk conditions. Major events are ACS within 12 months, another prior MI, ischemic stroke, or symptomatic PAD; do not count the same infarction twice. High-risk conditions are age at least 65, coronary bypass or PCI, current smoking, diabetes, heart failure, hypertension, or LDL cholesterol at least 100 mg/dL despite maximally tolerated statin plus ezetimibe. Very-high-risk goals are LDL below 55 and non-HDL below 85 mg/dL. Other clinical ASCVD generally has goals below 70 and 100 mg/dL, respectively; further lowering may be reasonable. Use high-intensity or maximally tolerated statin therapy and add appropriate nonstatin treatment when needed. See the [2026 dyslipidemia guideline, Figure 10 and secondary prevention recommendations](https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001423).
Apply it
Recurrent MIs establish very high risk. A single MI in a patient with both PCI and hypertension also qualifies. By contrast, a 50-year-old with one MI and PCI but none of the other listed conditions has only one high-risk condition and does not automatically qualify. LDL of 62 mg/dL exceeds the very-high-risk goal. Recheck lipids 4–8 weeks after treatment changes.
Common pitfall: Do not equate any single ASCVD event with very high risk or use the older 70-mg/dL intensification threshold as a universal goal.
Cardiac Imaging and Assessment9%
52.How is fractional flow reserve calculated and interpreted?
FFR is the ratio of distal coronary pressure to aortic pressure during maximal hyperemia, when microvascular resistance is minimized and relatively stable. For an angiographically intermediate lesion, an FFR of 0.80 or less supports physiological significance in the appropriate clinical setting. Values above 0.80 generally support deferring PCI in stable patients. Reliable interpretation requires pressure equalization, adequate hyperemia, exclusion of significant drift, and recognition that serial or diffuse disease complicates lesion-level attribution.
Apply it
During stable maximal hyperemia, distal pressure is 72 mm Hg and aortic pressure is 90 mm Hg. Calculate FFR as 0.80, then integrate this threshold result with symptoms, anatomy, and measurement quality.
Common pitfall: Do not calculate FFR from resting pressures and call it a hyperemic result. A mathematically correct ratio remains unreliable if pressure drift or inadequate hyperemia undermines the measurement.
ACC Coronary Interventions Handbook, Chapter 5: Physiological Assessment of Coronary Lesions
53.How does iFR differ from FFR in lesion assessment?
The instantaneous wave-free ratio evaluates a distal-to-aortic pressure relationship during a selected diastolic period at rest, avoiding pharmacological hyperemia. FFR measures the pressure ratio during maximal hyperemia. The commonly used decision thresholds differ: iFR at or below 0.89 and FFR at or below 0.80 support significance in the appropriate setting. Borderline or discordant results require attention to technical quality, diffuse disease, and the clinical question rather than averaging the two values.
Apply it
An intermediate lesion has a technically sound iFR of 0.93 in a stable patient. Recognize that the result supports deferral of PCI rather than applying the FFR threshold or requiring adenosine to validate every resting measurement.
Common pitfall: Do not apply the FFR cutoff to iFR. The methods sample different physiological conditions, and numerical similarity does not make their decision thresholds interchangeable.
ACC Coronary Interventions Handbook, Chapter 5: Physiological Assessment of Coronary Lesions
54.Why must blood be displaced during OCT acquisition?
OCT uses near-infrared light to obtain high-resolution intravascular images. Red blood cells scatter light and obscure the vessel wall, so a transient blood-clearing flush is required during acquisition. Inadequate clearing can create uninterpretable images or artifacts that resemble disease. OCT offers detailed assessment of stent struts and superficial tissue but has more limited tissue penetration than IVUS. Acquisition requirements and additional contrast exposure influence which modality best answers a particular question.
Apply it
An OCT pullback shows diffuse obscuration rather than a clearly defined lumen. Check blood clearance and acquisition conditions before diagnosing thrombus or tissue abnormality, and consider whether another imaging modality would better suit the patient.
Common pitfall: Do not interpret an inadequately cleared OCT image as reliable vessel anatomy. High nominal resolution cannot recover information hidden by blood scattering or a poor acquisition.
ACC Coronary Interventions Handbook, Chapter 13: Optical Coherence Tomography
55.How does coronary flow reserve reveal limitations beyond epicardial stenosis?
Coronary flow reserve compares maximal hyperemic coronary flow with resting flow. A reduced reserve can result from an epicardial stenosis, microvascular dysfunction, elevated resting flow, or combinations of these factors. FFR instead evaluates the pressure consequence of epicardial disease under hyperemia. The measurements therefore answer related but different questions. A preserved FFR with reduced flow reserve should prompt consideration of microvascular or resting-flow abnormalities rather than automatic implantation of an epicardial stent.
Apply it
A patient has persistent exertional symptoms, no flow-limiting focal stenosis by pressure assessment, and reduced coronary flow reserve. Investigate microvascular and resting-flow contributors instead of assuming that additional epicardial stenting must improve perfusion.
Common pitfall: Reduced coronary flow reserve does not localize the abnormality to a single epicardial lesion. Avoid interpreting it as interchangeable with a lesion-specific pressure ratio.
ACC Coronary Interventions Handbook, Chapter 5: Physiological Assessment of Coronary Lesions
56.How can operators reduce radiation without sacrificing necessary information?
Radiation reduction begins with obtaining only the imaging needed for the clinical task. Use appropriate lower pulse and acquisition rates, tight collimation, limited magnification, and fluoroscopy storage instead of unnecessary cine when suitable. Keep the detector close to the patient and avoid prolonged use of steep angulations that increase exposure. Monitor dose indicators during complex procedures. Fluoroscopy time alone is incomplete because acquisition settings, patient size, and projection strongly affect delivered radiation.
Apply it
During a prolonged complex PCI, reassess pulse rate, collimation, magnification, detector position, and repeated cine use. Adjust imaging technique while monitoring dose rather than waiting for fluoroscopy time alone to signal excessive exposure.
Common pitfall: Do not assume a short procedure always delivers a low dose. High-dose acquisition settings and difficult projections can produce substantial exposure even with limited fluoroscopy time.
Miscellaneous6%
57.How are absolute risk reduction and number needed to treat calculated?
Absolute risk reduction is the control-group event risk minus the treatment-group event risk over a specified period. Number needed to treat is the reciprocal of that absolute reduction expressed as a proportion. A reduction from 12% to 8% gives an absolute reduction of 4 percentage points and an NNT of 25. The time horizon, endpoint, baseline risk, and uncertainty must accompany interpretation because the same relative effect can yield very different absolute benefits.
Apply it
A hypothetical two-year trial reports events in 15% of controls and 10% of treated patients. Calculate an absolute reduction of 5 percentage points and an NNT of 20 for that endpoint over two years.
Common pitfall: Do not invert the relative risk reduction or a percentage written as a whole number. NNT also loses meaning when detached from the endpoint and follow-up period.
Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions
58.Why does statistical nonsignificance not establish treatment equivalence?
A result that does not reach statistical significance may reflect a small effect, inadequate precision, or both. The confidence interval shows which effect sizes remain compatible with the data under the analysis assumptions. If it includes meaningful benefit and harm, the study does not resolve the clinical comparison. Equivalence and noninferiority require an appropriate design and prespecified margins; they cannot be inferred simply because a superiority comparison has a P value above a conventional threshold.
Apply it
A trial reports a nonsignificant treatment comparison with a wide confidence interval spanning substantial benefit and harm. Describe the estimate as imprecise rather than telling patients that the procedures have been proven equally effective.
Common pitfall: Do not translate “no statistically significant difference” into “no difference.” Examine the interval, study design, and clinically important effects before drawing an equivalence conclusion.
Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions
59.How should shared decisions and the Heart Team guide revascularization?
Shared decision-making connects evidence about medical therapy, PCI, and CABG to the patient’s priorities, risks, and ability to follow treatment. When the optimal strategy is unclear, a multidisciplinary Heart Team can assess anatomy, operative risk, expected outcomes, and completeness of revascularization. Consent requires discussion of meaningful benefits, harms, and alternatives rather than a signature alone. Explain whether the proposed intervention aims chiefly at symptoms, survival, or another outcome that matters to the patient.
Apply it
A patient with complex multivessel disease strongly prefers rapid recovery but has anatomy favoring surgery. Use Heart Team assessment to explain the competing outcomes and recovery burdens, then incorporate the patient’s informed goals into the recommendation.
Common pitfall: Do not equate patient preference with an informed choice until alternatives and outcome differences have been explained. Equally, a technically preferred strategy does not eliminate the patient’s values.
2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
60.How should procedural outcome data guide quality improvement?
A procedural outcome rate is interpretable only when its numerator, denominator, endpoint definition, follow-up interval, and patient population are clear. A change in crude mortality may reflect different case mix rather than altered care quality. Quality review should examine comparable populations, uncertainty, and relevant care processes before assigning a cause. The certification blueprint includes clinical quality measurement, performance improvement, and adverse-event reporting; statistical interpretation helps turn those data into defensible improvement decisions.
Apply it
A laboratory’s mortality rate rises after it becomes a regional shock referral center. Examine case mix, endpoint definitions, and comparable risk groups before concluding that performance deteriorated, then review modifiable processes within those groups.
Common pitfall: Do not rank operators or institutions from unadjusted percentages alone. Small denominators, inconsistent definitions, and different patient severity can create misleading apparent differences in performance.
Interventional Cardiology Blueprint: Certification Examination (CERT), January 2026 · Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Prioritize Case Selection and Management and Procedural Techniques, each representing 20% of the official blueprint.
- Separate symptom-driven intervention from prognostic indications, and distinguish stable multivessel ACS from cardiogenic shock.
- Match procedural problems to mechanisms: inadequate support, calcium, underexpansion, side-branch compromise, and microvascular obstruction.
- Recognize perforation, tamponade, stent thrombosis, and concealed access bleeding through their discriminating clinical cues.
- Retain structural and peripheral breadth: dobutamine interpretation in low-gradient stenosis, TAVR versus SAVR selection, commissurotomy suitability, TEER criteria, ABI, and limb-threatening ischemia.
- Practise Fick flow and shunt calculations, coronary-anomaly surgical criteria, platelet and coagulation physiology, medication transitions, and current risk-specific lipid goals.
- Interpret the OCT and IVUS teaching images by tracing lumen and strut boundaries, comparing reference dimensions, and locating tissue or calcium before choosing treatment.
- Use the complete January 2026 official outline to identify additional topics beyond these 60 selected concepts.
A practical preparation plan
1. Map the complete certification outline
Read all nine official domains and their detailed topics. Mark each as secure, uncertain, or unstudied. Use the published weights to allocate effort while preserving coverage of smaller domains.
2. Build revascularization decision comparisons
Compare medical therapy, PCI, and CABG for stable symptoms, diabetes with multivessel disease, left main disease, ACS, and shock. State the intended outcome and the finding that changes the recommendation. Distinguish immediate rescue angiography after failed fibrinolysis from routine angiography 2–24 hours after apparent success. For prior CABG, distinguish the 2021 target-selection recommendation from subsequent randomized evidence and compare procedural complexity.
3. Rehearse mechanism-based procedural planning
For each lesion, specify access, equipment needs, lesion preparation, imaging questions, and likely failure points. Explain what you would reassess before escalating force, adding metal, or changing devices.
4. Practise complication discrimination
Use brief scenarios to distinguish epicardial obstruction from no-reflow, hemorrhage from tamponade, and mechanical infarct complications from uncomplicated pump failure. Pair each diagnosis with its immediate mechanism-directed response.
5. Integrate physiology, images, and medications
Calculate pressure ratios, systemic and pulmonary flows, shunt ratios, and absolute effects. In each imaging schematic, first trace the lumen and scaffold, then compare areas and tissue patterns; explain how the visible findings change treatment. Review complete clinical pullbacks to assess longitudinal abnormalities. Identify unreliable measurements and OCT acquisition artifacts. For medication decisions, specify contraindications, organ function, bleeding risk, transition timing, and the current treatment goal.
6. Use drills to diagnose learning gaps
Answer the 20 questions before reading explanations, then explain why every alternative is less appropriate. Review missed mechanisms with the flashcards and relevant primary references; do not interpret the drill score as a pass prediction.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABIM Interventional Cardiology Certification Policies
- ABIM Blueprints
- Interventional Cardiology Blueprint: Certification Examination (CERT), January 2026
- ABIM Expanded Blueprints
- 2021 ACC/AHA/SCAI Coronary Artery Revascularization Guideline Slide Set
- 2025 Acute Coronary Syndromes Guideline: Top Things to Know
- SCAI Publishes Expert Consensus Statement on Management of Calcified Coronary Lesions
- European Bifurcation Club 18th Expert Consensus Document, 2024
- SCAI: How to Prevent and Treat No Reflow Using Evidence-Based Measures
- SCAI: Management of Distal Coronary Artery Perforation
- 2020 ACC/AHA Valvular Heart Disease Guideline Slide Set
- 2024 AHA/ACC Peripheral Artery Disease Guideline Slide Set
- ACC Coronary Interventions Handbook, Chapter 8: In-Stent Restenosis
- STS Adult Cardiac Surgery Database Training Manual, Version 2.9, November 2018
- DailyMed: Prasugrel Prescribing Information
- CPIC Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
- ACC Coronary Interventions Handbook, Chapter 5: Physiological Assessment of Coronary Lesions
- ACC Coronary Interventions Handbook, Chapter 13: Optical Coherence Tomography
- ACC Coronary Interventions Handbook, Chapter 3: Femoral Arterial Access
- ACC Coronary Interventions Handbook, Chapter 15: Management of Complications
- SCAI Expert Consensus Statement on Management of In-Stent Restenosis and Stent Thrombosis
- SCAI: Tips and Tricks for Radiation Safety and Reduction
- Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions
- SCAI Expert Consensus Statement on Management of In-Stent Restenosis and Stent Thrombosis - PMC
- AHA Scientific Statement: Mechanical Complications of Acute Myocardial Infarction A Scientific Statement from the American Heart Association - PMC
- DailyMed - KENGREAL- cangrelor injection, powder, lyophilized, for solution
- Prevention and Management of Left Main Coronary Artery Dissection | SCAI
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.